Globus Medical (NYSE:GMED) Beats Q2 CY2026 Sales Expectations
Globus Medical (NYSE:GMED) reported Q2 CY2026 revenue of $789.6 million, up 5.9% year on year and 0.9% above analysts’ estimates, according to the company. Non-GAAP EPS was $1.34, 21.9% above consensus. The company guided full-year revenue to about $3.2 billion, near estimates.
How this was made
The 30-second read
Why it matters
Q2 results beat revenue and adjusted EPS estimates, with operating margin improvement, but the forward revenue growth outlook implies slower momentum ahead.
Market read
This is a single-name earnings beat with margin strength, likely supporting near-term positioning, while forward growth expectations introduce a caution flag.
What to watch
The beat is partly framed around excluding Nevro and share gains; traders may want to verify whether growth is sustainable across product cycles and whether FX headwinds persist.
Background
Globus Medical is a spine-focused medical device company reporting Q2 CY2026 results with commentary on underlying business growth and margin trends.
Ticker impact
Globus Medical reported Q2 CY2026 revenue of $789.6M, up 5.9% YoY, and adjusted EPS of $1.34 above consensus.
Near-term upside bias versus consensus expectations, but follow-through depends on whether the implied demand deceleration materializes.
The article provides concrete Q2 outperformance (revenue and EPS) plus margin improvement, but also notes next-12-month revenue growth expectations decelerate to 4.8%.
Market effects
Supports sentiment for spine/orthopedic medical device demand and pricing power, given share gains and margin expansion.
International Spine growth (14% as-reported, 12% constant currency) suggests currency-neutral demand strength.
Limited broader market impact; primarily a single-name read-through for medtech growth and profitability trends.
Counterpoint
The article flags a deceleration in expected revenue growth (4.8% over 12 months), which could cap multiple expansion despite the beat.
Key entities
- companyGlobus Medical
Reported Q2 CY2026 revenue $789.6M (+5.9% YoY) and adjusted EPS $1.34, and guided full-year revenue around $3.2B.
- executiveKeith Pfeil
CEO who attributed growth to share gains, including US Spine and International Spine.